GSK PLC Faces Scrutiny Over Asthma Inhaler Discontinuation
GSK PLC, a pharmaceutical company in the Health Care sector, has announced its decision to discontinue a widely used asthma inhaler for children in the US. This move has prompted an investigation by US Senator Maggie Hassan.
Investigation Initiated by US Senator Maggie Hassan
US Senator Maggie Hassan has initiated an investigation into GSK PLC’s decision to discontinue the asthma inhaler. The investigation aims to assess the potential impact on patients and Medicaid rebates.
Price Reduction of Malaria Vaccine
GSK PLC has made a commitment to reduce the price of its malaria vaccine, RTS,S. The price reduction is a result of collaboration with Bharat Biotech, aimed at making the vaccine more accessible in endemic countries.
Company Stock Performance
GSK PLC’s stock price has remained relatively stable, hovering around its 52-week high, despite the developments surrounding its asthma inhaler discontinuation and malaria vaccine price reduction.
Key Facts
- GSK PLC has discontinued a widely used asthma inhaler for children in the US.
- An investigation has been initiated by US Senator Maggie Hassan.
- GSK PLC has committed to reducing the price of its malaria vaccine, RTS,S.
- The company’s stock price has remained stable, hovering around its 52-week high.